How to Help Your Patients Find Lofexidine in Stock: A Provider's Guide

You've made the clinical decision to prescribe lofexidine (Lucemyra) for a patient undergoing opioid withdrawal. But writing the prescription is just step one. If your patient can't fill it — or experiences significant delay — the treatment window closes and relapse risk rises. This guide gives providers a practical, step-by-step workflow to maximize the likelihood that patients successfully fill their lofexidine prescription.

Why Lofexidine Fills Are Often Delayed

Most retail pharmacies don't routinely stock lofexidine. Its high cost (~$2,333 retail for a standard supply), low prescription volume relative to other medications, and specialty classification mean patients sent to a typical chain pharmacy often find empty shelves or pharmacists unfamiliar with the drug. Add a prior authorization requirement from the insurer, and the prescription can be delayed by days — a lifetime when a patient is in acute withdrawal.

Step 1: Identify the Right Pharmacy Before Prescribing

The best time to address the pharmacy access problem is before writing the prescription. Develop a short list of pharmacies in your area that reliably carry or can quickly order lofexidine. This may include:

Your affiliated hospital's outpatient pharmacy

Specialty pharmacies in your region that serve addiction treatment programs

Large-volume chain pharmacy locations in your metro area

Mail-order pharmacy options for patients who have lead time

Calling these pharmacies yourself (or having staff do so) at the time of prescribing — rather than leaving it entirely to the patient — significantly improves fill rates. Send the prescription electronically to the pharmacy you've confirmed has stock.

Step 2: Proactively Manage Insurance Prior Authorization

Many insurance plans require prior authorization for lofexidine, often citing cost and preference for alternative withdrawal management strategies. To minimize delays:

Check coverage before the appointment if possible using the patient's insurance information

Document clinical rationale clearly in the chart: use case, contraindications to alternatives, timeline urgency

Submit the PA request the same day as the prescription

Request expedited/urgent review given the clinical urgency of opioid withdrawal management

Step 3: Equip Patients with Cost-Saving Resources

Cost is a major barrier. The retail price of lofexidine exceeds $2,333 for a standard supply. However, patients have multiple options to dramatically reduce this:

GoodRx coupon: As low as approximately $383 — an 84% reduction from retail.

BioCorRx/Lucemyra commercial access program: Patients with commercial insurance (not Medicare/Medicaid) may qualify for savings or rebates through the LUminate Support Program. Encourage patients to visit lucemyra.com for current program details.

Prescription Hope patient assistance: For lower-income or uninsured patients, Prescription Hope can access lofexidine for approximately $70/month through manufacturer patient assistance programs.

Step 4: Refer Patients to medfinder for Pharmacy Locating

Rather than leaving patients to call pharmacies themselves, refer them to medfinder. Patients enter their medication name, dosage, and location. medfinder contacts pharmacies, checks stock, and texts the patient the results. For patients already experiencing withdrawal symptoms — who may be in significant discomfort — this reduces the burden of navigating the pharmacy system on their own.

Step 5: Have a Clear Fallback Plan

Even with a proactive approach, some patients will encounter delays. Brief your patient at the time of prescribing:

If fill is delayed, call your office immediately — don't try to manage withdrawal alone

Have a clonidine bridge prescription or order ready in case lofexidine cannot be found within 24 hours

Discuss supportive OTC measures for specific symptoms (anti-emetics, antidiarrheal agents, NSAIDs for aches)

The Bigger Picture: Access as a Treatment Quality Issue

Patients in withdrawal who encounter prescription delays are at significantly elevated risk of relapse — often before withdrawal symptoms peak. For providers managing OUD, medication access logistics are as much a part of the treatment plan as the clinical decision itself. As covered in our provider shortage briefing, proactive access management reduces drop-out during the critical early withdrawal phase.